Literature DB >> 20703482

[Current TNM classification systems for adrenocortical carcinoma].

M Fassnacht1, C Wittekind, B Allolio.   

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy and often difficult to diagnose. It was only in 2003 that the UICC proposed the first TNM classification for ACC. However, an analysis based on data from the German ACC Registry revealed several shortcomings of this classification; in particular, the outcome of patients with UICC stage II and III was not significantly different. Therefore, the European Network for the Study of Adrenal Tumours (ENSAT) developed a revised staging system, the superiority of which was recently confirmed in an independent American cohort. In the ENSAT classification, stage I (tumors ≤ 5 cm) and II (tumors < 5 cm) are non-infiltrating tumors without positive lymph nodes and distant metastases. Stage III is defined by the presence of positive lymph nodes, infiltration of surrounding tissue, or venous tumor thrombus. Stage IV is restricted to patients with distant metastasis. Since the ENSAT classification better reflects patient prognosis than the UICC classification, its use for future clinical and research purposes is recommended. Furthermore, exact documentation of the resection status is essential for optimal decisions on treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20703482     DOI: 10.1007/s00292-010-1306-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  26 in total

1.  Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data.

Authors:  A J Hough; J W Hollifield; D L Page; W H Hartmann
Journal:  Am J Clin Pathol       Date:  1979-09       Impact factor: 2.493

2.  Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.

Authors:  David Brix; Bruno Allolio; Wiebke Fenske; Ayman Agha; Henning Dralle; Christian Jurowich; Peter Langer; Thomas Mussack; Christoph Nies; Hubertus Riedmiller; Martin Spahn; Dirk Weismann; Stefanie Hahner; Martin Fassnacht
Journal:  Eur Urol       Date:  2010-06-22       Impact factor: 20.096

3.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 4.  Adrenocortical carcinoma: clinical and laboratory observations.

Authors:  B L Wajchenberg; M A Albergaria Pereira; B B Medonca; A C Latronico; P Campos Carneiro; V A Alves; M C Zerbini; B Liberman; G Carlos Gomes; M A Kirschner
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

5.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

Authors:  Gwenaelle Abiven; Joel Coste; Lionel Groussin; Philippe Anract; Frédérique Tissier; Paul Legmann; Bertrand Dousset; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2006-05-02       Impact factor: 5.958

6.  An eleven-year experience with adrenocortical carcinoma.

Authors:  R F Pommier; M F Brennan
Journal:  Surgery       Date:  1992-12       Impact factor: 3.982

7.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

Authors:  J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

8.  The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.

Authors:  Giovanni Lughezzani; Maxine Sun; Paul Perrotte; Claudio Jeldres; Ahmed Alasker; Hendrik Isbarn; Lars Budäus; Shahrokh F Shariat; Giorgio Guazzoni; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Eur J Cancer       Date:  2010-01-13       Impact factor: 9.162

9.  Adrenal cortical carcinoma in Norway, 1970-1984.

Authors:  J A Søreide; K Brabrand; S O Thoresen
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

10.  Surgical management, DNA content, and patient survival in adrenal cortical carcinoma.

Authors:  J E Lee; D H Berger; A K el-Naggar; R C Hickey; R Vassilopoulou-Sellin; R F Gagel; M A Burgess; D B Evans
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

View more
  6 in total

1.  [TNM 2010. What's new?].

Authors:  C Wittekind
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  Suppression of cytochrome P450 4B1: An early event in adrenocortical tumorigenesis.

Authors:  Timothy D Murtha; Reju Korah; Tobias Carling
Journal:  Surgery       Date:  2016-11-16       Impact factor: 3.982

3.  A rare coexistence of non-functional adrenocortical carcinoma and multicentric papillary thyroid microcarcinoma: a case report.

Authors:  Melia Karakose; Oguz Hasdemir; Erman Cakal; Tuncay Delibasi
Journal:  J Med Case Rep       Date:  2013-07-26

4.  Adrenocortical carcinoma in patients with MEN1: a kindred report and review of the literature.

Authors:  Weixi Wang; Rulai Han; Lei Ye; Jing Xie; Bei Tao; Fukang Sun; Ran Zhuo; Xi Chen; Xiaxing Deng; Cong Ye; Hongyan Zhao; Shu Wang
Journal:  Endocr Connect       Date:  2019-03-01       Impact factor: 3.335

5.  Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma.

Authors:  Jonathan Poirier; Nadia Gagnon; Massimo Terzolo; Soraya Puglisi; Nada El Ghorayeb; Anna Calabrese; André Lacroix; Isabelle Bourdeau
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

6.  Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art.

Authors:  Amir H Lebastchi; John W Kunstman; Tobias Carling
Journal:  J Oncol       Date:  2012-10-18       Impact factor: 4.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.